Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

UK study aims to crack the code of brain tumours with genetic testing

NCT ID NCT04274283

Knowledge-focused Sponsor: University of Birmingham Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This UK study is building a network to rapidly analyze the genetics of brain tumours (gliomas) from 1000 patients. By combining tumour and blood samples, researchers hope to classify each tumour more precisely. The goal is to create a system that can quickly match patients with the right targeted therapies in future trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could create a system to quickly identify the exact genetic makeup of brain tumours, making it easier to test and deliver personalized treatments.
What could go wrong
This is a feasibility study focused on building infrastructure, not testing a treatment. It may not directly improve outcomes for participants, and the hoped-for targeted therapy trials may not follow.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2020

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

* Patients with a newly diagnosed suspected WHO Grade 2-4 glioma, (as evidenced radiologically) AND suitable for a diagnostic or therapeutic surgical procedure resulting in a frozen tumour sample matched to a blood sample. * Patients with progression with known WHO Grade 2-4 glioma (those with available frozen tumour will be prioritised for detailed genomic analysis).

Ages

16 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Newly diagnosed suspected WHO Grade 2-4 glioma, (as evidenced radiologically) AND suitable for a diagnostic or therapeutic surgical procedure resulting in a tumour sample matched to a blood sample. * Patients with progression with known WHO Grade 2-4 glioma (those with available frozen tumour will be prioritised for detailed genomic analysis). * Valid written informed consent for the study. Exclusion Criteria: * Primary spinal cord tumours * Active treatment of other malignancy * Contraindication to MRI * Patients without standard of care imaging available

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOMA

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust

    TERMINATED

    Cambridge, CB2 0QQ, United Kingdom

  • Charing Cross Hospital, Imperial College Healthcare NHS Trust

    RECRUITING

    London, W6 8RF, United Kingdom

  • Churchill Hospital, Oxford University Hospitals NHS Foundation Trust

    RECRUITING

    Oxford, OX3 9DU, United Kingdom

  • Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust

    RECRUITING

    Newcastle upon Tyne, NE7 7DN, United Kingdom

  • King's College Hospital, King's College Hospital NHS Foundation Trust

    RECRUITING

    London, SE5 9RS, United Kingdom

  • NHS Lothian

    ACTIVE_NOT_RECRUITING

    Edinburgh, EH4 2XU, United Kingdom

  • Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust

    RECRUITING

    Birmingham, B15 2TH, United Kingdom

  • Queen Elizabeth Unviersity Hospital, NHS Greater Glasgow and Clyde Health Board

    ACTIVE_NOT_RECRUITING

    Glasgow, G51 4TF, United Kingdom

  • Queen's Medical Centre, Nottingham University Hospitals NHS Trust

    RECRUITING

    Nottingham, NG7 2UH, United Kingdom

  • Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust

    RECRUITING

    Manchester, M6 8HD, United Kingdom

  • St James's University Hospital, Leeds Teaching Hospitals NHS Trust

    RECRUITING

    Leeds, LS9 7TF, United Kingdom

  • The Christie Hospital, The Christie NHS Foundation Trust

    RECRUITING

    Manchester, M20 4BX, United Kingdom

  • The Walton Centre, The Walton Centre NHS Foundation Trust

    RECRUITING

    Liverpool, L9 7LJ, United Kingdom

  • Velindre Cancer Centre, Velindre University NHS Trust

    RECRUITING

    Cardiff, CF14 2TL, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.